<DOC>
	<DOC>NCT01332487</DOC>
	<brief_summary>This retrospective study aims to assess the impact of early vs delayed 5-alpha-reductase inhibitor (5ARI) therapy in patients with BPH on alpha-blocker (AB) therapy and the risk of acute urinary retention (AUR), prostate-related surgery, and emergency surgery (defined as prostate surgery occurring within 30 days of AUR). The MarketScan database will be utilized for this study (2000-2008).</brief_summary>
	<brief_title>Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<criteria>Male aged 50 years or older diagnostic claim for BPH prescription claim for an AB and a 5ARI in the observation period (5ARI must occur within a 6month window after the AB). continuously eligible for 6 months prior to and 12 months after index prescription date prostate or bladder cancer during the study period any prostaterelated surgical procedure within 5 months of the index prescription date prescription claim for finasteride 1 mg for male pattern baldness during the study period 5ARI therapy prior to initiation of AB therapy</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>5-alpha-reductase inhibitor</keyword>
	<keyword>prostate surgery</keyword>
	<keyword>alpha-blocker</keyword>
	<keyword>enlarged prostate</keyword>
	<keyword>acute urinary retention</keyword>
	<keyword>Benign prostatic hyperplasia</keyword>
</DOC>